CLINICAL TRIAL
Treatment for Solid Organ Transplant
Waitlist Available · 18+ · All Sexes · Los Angeles, CA
Trial to Compare the SherpaPak™ Device vs Cold Storage
See full descriptionAbout the trial for Solid Organ Transplant
Treatment Groups
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.
Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:View All
for a transplant at our hospital, UCLA
People who need a transplant must find a donor who is not local. show original
Any person aged 18 or over who is of either sex is eligible for a heart transplant. show original
Odds of EligibilitySimilar Trials
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Approximate Timelines
Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 30 days post-transplant
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like
Measurement Requirements
This trial is evaluating whether Treatment will improve 1 primary outcome and 3 secondary outcomes in patients with Solid Organ Transplant. Measurement will happen over the course of 24 hours post-transplant.
Absence of moderate to severe primary graft dysfunction (left or right ventricle)
24 HOURS POST-TRANSPLANT
Percentage of subjects without moderate to severe primary graft dysfunction (left or right ventricle)Quantify Hemodynamic parameters
24 HOURS POST-TRANSPLANT
Percentage of Cardiac index, cardiac output, blood pressure, mean arterial pressure, pulmonary artery pressure, left atrial pressure, right atrial pressure, right ventricular pressure, stroke volume and ejection fractionIncidence of antibody mediated rejection
30 DAYS POST-TRANSPLANT
Percentage of subjects with no antibody mediated rejection in the first 30 days after transplant.Incidence of acute cellular rejection
30 DAYS POST-TRANSPLANT
Percentage of subjects without acute cellular rejection in the first 30 days after transplantWho is running the study
Principal InvestigatorF. E.
Prof. Fardad Esmailian, Professor of Surgery
Cedars-Sinai Medical Center
Patient Q & A Section
Ask a question about the study
Other questions from users
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any geographic restrictions to consider when applying for this trial?
Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.
Will my insurance cover participating in this trial?
In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.
See if you qualify for this trial
Get access to this novel treatment for Solid Organ Transplant by sharing your contact details with the study coordinator.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Power